Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

$43.06
+0.70 (+1.65%)
(As of 11:12 AM ET)

Ionis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 21 Wall Street analysts who have issued ratings for Ionis Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 1 has given a sell rating, 6 have given a hold rating, 12 have given a buy rating, and 2 have given a strong buy rating for IONS.

Consensus Price Target

$60.68
40.93% Upside
High Forecast$82.00
Average Forecast$60.68
Low Forecast$37.00

According to the 21 analysts' twelve-month price targets for Ionis Pharmaceuticals, the average price target is $60.68. The highest price target for IONS is $82.00, while the lowest price target for IONS is $37.00. The average price target represents a forecasted upside of 40.93% from the current price of $43.06.

TypeCurrent Forecast
9/20/23 to 9/19/24
1 Month Ago
8/21/23 to 8/20/24
3 Months Ago
6/22/23 to 6/21/24
1 Year Ago
9/20/22 to 9/20/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
5 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$60.68$60.68$58.43$47.80
Forecasted Upside40.93% Upside28.09% Upside30.37% Upside27.50% Upside

IONS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IONS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Ionis Pharmaceuticals Stock vs. The Competition

TypeIonis PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.77
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside40.93% Upside977.99% Upside6.72% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/26/2024JPMorgan Chase & Co.
3 of 5 stars
 Boost TargetNeutral ➝ Neutral$50.00 ➝ $55.00+17.25%
8/2/2024Guggenheim
3 of 5 stars
 Boost TargetBuy ➝ Buy$64.00 ➝ $70.00+42.86%
8/2/2024The Goldman Sachs Group
2 of 5 stars
S. Richter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSell ➝ Sell$33.00 ➝ $37.00-24.40%
8/2/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$45.00 ➝ $51.00+4.74%
8/2/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00+16.91%
8/2/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Biliouris
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$67.00 ➝ $60.00+16.91%
Trump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absolute (Ad)

Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.

This means you must act NOW before it's too late.
7/24/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Foroohar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/24/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$53.00 ➝ $62.00+22.94%
7/23/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$54.00 ➝ $59.00+16.79%
7/23/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$67.00 ➝ $68.00+34.36%
7/16/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageUnderperform ➝ Buy$29.00 ➝ $75.00+57.66%
6/27/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$50.00 ➝ $53.00+11.11%
6/14/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Pickering
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform$44.00+7.00%
5/8/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$85.00 ➝ $82.00+101.72%
4/10/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradePeer Perform ➝ Outperform$58.00+35.42%
4/9/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
4/9/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$72.00 ➝ $75.00+77.56%
2/22/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$62.00 ➝ $63.00+42.15%
1/26/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$65.00 ➝ $70.00+35.92%
11/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$45.00 ➝ $48.00+9.76%
9/28/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageStrong-Buy$63.00+36.19%
7/31/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$36.00 ➝ $60.00+50.79%
5/4/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
2/23/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$34.00 ➝ $27.00-26.63%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:50 AM ET.

IONS Forecast - Frequently Asked Questions

What is Ionis Pharmaceuticals' forecast for 2024?

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Ionis Pharmaceuticals is $60.68, with a high forecast of $82.00 and a low forecast of $37.00.

Should I buy or sell Ionis Pharmaceuticals stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 6 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IONS shares.

Does Ionis Pharmaceuticals's stock price have much upside?

According to analysts, Ionis Pharmaceuticals's stock has a predicted upside of 28.73% based on their 12-month stock forecasts.

Has Ionis Pharmaceuticals been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, Ionis Pharmaceuticals's stock had 2 upgrades and 1 downgrade by analysts.

What analysts cover Ionis Pharmaceuticals?
Do Wall Street analysts like Ionis Pharmaceuticals more than its competitors?

Analysts like Ionis Pharmaceuticals less than other "medical" companies. The consensus rating score for Ionis Pharmaceuticals is 2.71 while the average consensus rating score for "medical" companies is 2.77. Learn more on how IONS compares to other companies.



This page (NASDAQ:IONS) was last updated on 9/19/2024 by MarketBeat.com Staff
From Our Partners